No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BCPC Balchem
- 153.500
- -0.100-0.07%
Trading Jun 3 11:14 ET
4.98BMarket Cap43.36P/E (TTM)
155.630High152.890Low11.73KVolume154.560Open153.600Pre Close1.80MTurnover0.04%Turnover Ratio45.82P/E (Static)32.42MShares159.52052wk High4.61P/B4.94BFloat Cap110.14352wk Low0.79Dividend TTM32.18MShs Float171.855Historical High0.51%Div YieldTTM1.78%Amplitude0.865Historical Low153.730Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Balchem Corporation to Present at the Wells Fargo Industrials Conference on June 12, 2024
MONTVALE, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the Wells Fargo
Here's Why Balchem (NASDAQ:BCPC) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usu
Form 144 | Balchem(BCPC.US) Insider Proposes to Sell 383.95K in Common Stocks
SEC FILLINGS DISCLOSED/ May 24, $Balchem(BCPC.US)$ Insider Griffin Jonathan Harrison intends to sell 2,500 shares of its common stock on May 24, with a total market value of approximately $383.95K.
Form 144 | Balchem(BCPC.US) Insider Proposes to Sell 232.48K in Common Stocks
SEC FILLINGS DISCLOSED/ May 21, $Balchem(BCPC.US)$ Insider Griffin Jonathan Harrison intends to sell 1,500 shares of its common stock on May 21, with a total market value of approximately $232.48K.
Balchem Corporation to Attend the Deutsche Bank Global Consumer Conference on June 4, 2024
MONTVALE, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will attend the Deuts
Insider Sale at Balchem Corp (BCPC): SVP & Chief Technology Officer Michael Sestrick Sells ...
Comments
Balchem Corporation's market sentiment has improved, as seen in its P/E ratio of 45.01. Despite slower EPS growth, the company's long-term track record and dividends have led to a favorable total shareholder return.
Balchem's (NASDAQ:BCPC) 13% CAGR Outpaced the Company's Earnings Growth Over the Same Five-year Period 1
The high P/E ratio for Balchem is down to investors foreseeing rapid growth outpacing the market. Despite slight falls, medium-term growth has pleased shareholders. Investors might pay more for the stock expecting strong future growth. This situation could maintain the stock's price.
Balchem's dedication to profit-sharing with shareholders is evident from its three-year median payout ratio of 21%. Yet, an enhancement in its ROE could prove beneficial, given the substantial reinvestment of profits. Expectations suggest an increase in company's earnings, despite its low ROE compared to the industry.
Despite lower-than-average share price increase, the market's consistent positive reception over the past five years suggests worthiness for long-term investments.
Gapping up
In reaction to earnings/guidance:
• $ChargePoint(CHPT.US$ +2.8%, $Designer Brands(DBI.US$ +1.8%, $Donaldson(DCI.US$ +0.7%
Other news:
• $Cepton(CPTN.US$ +9.2% (receives non-bindingLolfor a $100mln investment from Koito Manufacturing)
• $Sorrento Therapeutics(SRNE.US$ +7.2% (receives FDA Fast Track Designation for SP-103(Lidocaine Topical System) 5.4%)
• $Mereo BioPharma(MREO.US$ +6.7% (sends letter to Rubric Capital...
In reaction to earnings/guidance:
• $ChargePoint(CHPT.US$ +2.8%, $Designer Brands(DBI.US$ +1.8%, $Donaldson(DCI.US$ +0.7%
Other news:
• $Cepton(CPTN.US$ +9.2% (receives non-bindingLolfor a $100mln investment from Koito Manufacturing)
• $Sorrento Therapeutics(SRNE.US$ +7.2% (receives FDA Fast Track Designation for SP-103(Lidocaine Topical System) 5.4%)
• $Mereo BioPharma(MREO.US$ +6.7% (sends letter to Rubric Capital...
9
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg